Psychiatr. pro Praxi, 2009; 10(6): 272-274

The antidepressants treatment in patients with high cardiovascular risk: benefit or risk?

MUDr. Radkin Honzák CSc1, MUDr. Milan Vrána, DrSc3,2
1 Psychiatrická katedra IPVZ, Ústav všeobecného lékařství 1. LF UK v Praze
2 Institut klinické a experimentální medicíny (IKEM), Praha
3 Psychiatrická léčebna Bohnice, Praha

Antidepressive treatment with sertraline, citalopram and paroxetine in patients with high cardiovascular risks is effective and safe

(group safety provided by results of clinical studies). The efficacy and safety of antidepressive drug in patients with severe depression

may be enhanced by means of primary and secondary prevention, ie. by beta-blockers or statins. Our recommendation is: to monitor

individual safety in patients with high cardiovascular risk before the start of antidepressant therapy and during its application by way

of monitoring heart rate variability (HRV) or at least by monitoring rest heart frequency. The treatment of serious depression/anxiety in

patients with cardiovascular disease should be guided in cooperation of psychiatrist and cardiologist.

Keywords: cardiovascular diseases, depression, anxiety, antidepressive drugs, efficacy, safety.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Honzák R, Vrána M. The antidepressants treatment in patients with high cardiovascular risk: benefit or risk? Psychiatr. praxi. 2009;10(6):272-274.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lichtman JH, Bigger T, Blumenthal JA, et al. Depression and coronary heart disease: Recomendations for screening, referral and treatment. Circulation 2008; 118: 1768-1775. Go to original source... Go to PubMed...
    2. Krombholz R. Deprese u seniorů. Practicus 2006: 431-433.
    3. van Zylt LT, Hasgawa T, Nagata K. Effects of antidepressants on heart rate variability in major depression. A quantitative review. Biopsychosoc Med 2008; 2: 12. Go to original source... Go to PubMed...
    4. Davidson J, Watkins l, Owens M, et al. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol 2005; 25: 480-484. Go to original source... Go to PubMed...
    5. Alvarez W, Pickworth KK. Safety of antidepressants in the patients with cardiac disease. Pharmacotherapy 2003; 23: 754-771. Go to original source... Go to PubMed...
    6. Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women. J Am Coll Cardiol 2009; 53: 950-958. Go to original source... Go to PubMed...
    7. Licht CMM, Geus EJC, Seldenrijk A, et al. Depression is associated with decrease blood pressure, but antidepressant use increase the risk of hypertension. Hypertension, 2009; 53: 631-638. Go to original source... Go to PubMed...
    8. Carney RM, Freeland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 2009; 166: 410-417. Go to original source... Go to PubMed...
    9. American Academy of Family Psysicians (AAFP): Guidelines for the detection and management of postmyocardial infarction depression. Ann Fam Med 2009; 7: 71-79. Go to original source... Go to PubMed...
    10. Hjalmarson A. Effect of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J cardiol 1997; 80(9B): 35J-39J. Go to original source... Go to PubMed...
    11. Fejfar Z, Vrána M, Lánská V, Horák O. Variabilita srdeční frekvence a riziko náhlé srdeční smrti. Cor Vasa 1994; 36: 299-309.
    12. Ridker PM, et al The JUPITER trial. Low LDL and low CRP best for reducing events in primary prevention. American College of Cardiology Scientific Session March 29, 2009; Orlando (USA).
    13. Vrána M, Honzák R. Léčba depresivní a úzkostné poruchy při ischemické chorobě srdeční Cor Vasa 2009; 50: 338-342.
    14. Parashar S, Rumsfeld JS, Spertus JA, et al. Time course of depression and outcome of myocardial infarction. Arch Int med 2006; 166: 2035-2043. Go to original source... Go to PubMed...
    15. Honzák R, Seifert B. Citalopram a sertralin - využití v ordinaci praktického lékaře. Praktický lékař 2004; 8(5): 234-240.
    16. Vrána M, Honzák R. Lze snížit kardiovaskulární riziko při ischemické chorobě srdeční léčbou deprese? Farmakoterapie 2006; 3: 318-324.
    17. Glassman AH, Bigger JT, Gaffney M, Van Zyl LT. Heart rate variability in acute coronary syndrome patients with major depression: influence of sertraline and mood.
    18. Carney RM, Steinmeyer B, Freeland K, et al. Nightime heart rate and survival in depressed patients post acute myocardial infarction. Psychosomatic medicine 2008; 70: 757-763. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.